{"id":144287,"date":"2025-08-14T05:31:21","date_gmt":"2025-08-14T05:31:21","guid":{"rendered":"https:\/\/www.europesays.com\/us\/144287\/"},"modified":"2025-08-14T05:31:21","modified_gmt":"2025-08-14T05:31:21","slug":"fort-worths-rainwater-charitable-foundation-and-partners-award-2-5m-in-neurodegenerative-disease-research-grants-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/144287\/","title":{"rendered":"Fort Worth’s Rainwater Charitable Foundation and Partners Award $2.5M in\u00a0Neurodegenerative Disease Research Grants \u00bb Dallas Innovates"},"content":{"rendered":"

The Fort Worth-based Rainwater Charitable Foundation, in collaboration with the Aging Mind Foundation, the Alzheimer\u2019s Association, and CurePSP, has announced $2.5 million in grants to fund five innovative research projects over the next two years emerging from the second annual Tauopathy Challenge Workshop.<\/strong><\/p>\n

\u201cWe\u2019re encouraged to see growing momentum around the Tauopathy Challenge Workshop, with partners such as the Aging Mind Foundation, the Alzheimer\u2019s Association, and CurePSP joining our mission to support these novel, high impact proposals,\u201d Jeremy Smith, president of the Rainwater Charitable Foundation, said in a statement. \u201cGiven the current constraints on research funding, our commitment remains steadfast in advancing primary tauopathy research. The insights gained from this workshop have the potential to significantly impact broader neurodegenerative disease research, bringing us closer to meaningful treatments for those affected.\u201d<\/p>\n

The foundation is one of the largest independent funders of primary tauopathy research.<\/p>\n

The foundation said that the Tauopathy Challenge Workshop is a funding program that convenes interdisciplinary experts around a single topic: addressing unmet needs in primary tauopathies. It said that by funding innovative research, it aims to support the development of treatments for these debilitating neurodegenerative diseases, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).<\/p>\n

According to the foundation the Tauopathy Challenge Workshop has grown in size and impact since its inception in 2023 and has awarded $4.5 million to support novel, mechanism-focused research aimed at uncovering new therapeutic and biomarker targets for these tau-driven neurodegenerative diseases.<\/p>\n

Tauopathy Challenge Workshop winners<\/p>\n

Five groundbreaking projects will be funded this year and led by esteemed international researchers:<\/p>\n

:: Eleanor Drummond, PhD, University of Sydney<\/strong> (Awarded $500,000): This research aims to uncover how abnormal protein aggregation beyond tau contributes to primary tauopathies, specifically PSP, CBD, and Pick\u2019s disease. Using advanced molecular techniques, Dr. Drummond will identify proteins in the human brain prone to forming pathological aggregates and determine whether these changes are shared across different tauopathies. By mapping the location of these proteins in brain tissue and testing whether tau drives their aggregation, the study seeks to clarify disease mechanisms, identify biomarkers, and explore whether these processes can be reversed in cell models\u2014ultimately guiding future therapeutic strategies.<\/p>\n

:: Leonard Petrucelli, PhD, Mayo Clinic<\/strong> (Awarded $500,000): This research explores whether lysosomal transmembrane protein 106B (TMEM106B) fibrils promote tau seeding and worsen PSP symptoms, by analyzing post-mortem brain samples and assessing correlations between protein levels, genetic variants, and disease severity. Using innovative tools in human neurons and mouse models, Dr. Petrucelli and his co-investigator, Dr. Michael Ward (National Institutes of Health), will test whether TMEM106B fibrils directly influence tau pathology and lysosomal dysfunction, potentially uncovering new mechanisms and therapeutic targets for PSP.<\/p>\n

:: Vijay Rangachari, PhD, The University of Southern Mississippi<\/strong> (Awarded $500,000): This research examines the potential interaction between two amyloid-forming proteins\u2014transactive response DNA binding protein 43 kDa (TDP-43) and tau\u2014in neurodegenerative diseases such as PSP and frontotemporal lobar degeneration (FTLD). While both proteins are known to independently form toxic aggregates, the work explores whether they can co-aggregate into \u201chybrid amyloids\u201d with unique structures and pathological effects. Dr. Rangachari aims to confirm the presence of these deposits in human brain tissue, understand their molecular characteristics, and assess their role in neuronal dysfunction\u2014with the hope of developing antibodies to detect these toxic agents in the brain.<\/p>\n

:: Wilfried Rossoll, PhD, Mayo Clinic<\/strong> (Awarded $500,000): This research aims to uncover how TDP-43 co-pathology influences tau pathology and contributes to neurodegeneration in PSP and CBD. By leveraging both innovative spatial proteomics discovery approaches in human post-mortem brain tissue and mechanistic studies in mouse brain tissue culture models, Dr. Rossoll will explore how these proteins interact and affect overall disease progression. Insights gained will pave the way for stronger tools for studying neurodegenerative disorders and developing effective treatments.<\/p>\n

:: Mikael Simons, MD, Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, DZNE<\/strong> (German Center for Neurodegenerative Diseases) (Awarded $500,000): This research investigates how non-neuronal cells, particularly glial cells like oligodendrocytes, and factors such as myelin damage and lipoproteins (particularly ApoE), contribute to tau aggregation and propagation. Using advanced imaging, biochemical assays, and both mouse models and human brain tissue, Dr. Simons aims to uncover whether disruptions in myelin and lipid transport systems play a critical role in tau pathology. The goal is to deepen understanding of tau-related disorders and identify potential therapeutic targets.<\/p>\n

Next round of funding<\/p>\n

The 2026 Tauopathy Challenge Workshop is open to all researchers via a letter of intent process, with applications for the next workshop open through Sept. 2. According to the foundation, the 2026 session is focused on exploring the structural and thermodynamic properties of tau and its interactions with other pathologies.<\/p>\n

Winners will collectively receive more than $2 million to fund their proposed neurodegenerative research, the foundation said.<\/p>\n

More on the supporting organizations<\/p>\n

The Rainwater Charitable Foundation (RCF) was created in the early 1990s by noted private equity investor and philanthropist Richard E. Rainwater.<\/p>\n

When Rainwater was diagnosed with a rare neurodegenerative disease and primary tauopathy called Progressive Supranuclear Palsy (PSP), the RCF expanded its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders, the foundation said. The RCF Medical Research Team supports that focus by managing the Tau Consortium, the Rainwater Prize Program, and the Tauopathy Challenge Workshop.<\/p>\n

The foundation said that with more than $140 million invested in medical research to date, the RCF has helped to advance eight treatments into human trials. Currently the RCF said it supports a range of programs, including a focus on family economic security, medical research, and other worthy causes.<\/p>\n

The Aging Mind Foundation (AMF) raises money to fund scientific research that seeks the causes of Alzheimer\u2019s disease and other types of dementia.<\/p>\n

The Alzheimer\u2019s Association is a worldwide voluntary health organization dedicated to Alzheimer\u2019s care, support, and research. The organization\u2019s mission is to lead the way to end Alzheimer\u2019s and all other dementia by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.<\/p>\n

CurePSP is a nonprofit organization dedicated to the awareness, care, and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA).<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n